[Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
There is a need in the management of non-Hodgkin's lymphoma (NHL) for tumor-targeted therapy. Immunotherapy with monoclonal antibodies can be used to reach this goal. These treatments have however often produced disappointing efficacy and so have not been broadly applicable to patients. MODIFIED MONOCLONAL ANTIBODIES: Technological advances have been used to alter mouse monoclonal antibodies genetically, leading to the development of mouse/human chimeric or humanized antibodies with demonstrated advantages of reduced immunogenicity and enhanced ability to interact with human effector cells. Initial phase I/II trials of monoclonal antibodies for relapse or refractory NHL, especially with chimeric anti-CD20 rituximab, demonstrated encouraging results. FURTHER ASSESSMENT: Randomized trials are now necessary to compare these agents with standard regimens and to determine their optimal use.
Jourdan
E
E
Médecine Interne B, CHU, Nïmes.
Richard
B
B
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D011379:Prognosis; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins; D000069283:Rituximab